Stock USRM U.S. STEM CELL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company U.S. Stem Cell, Inc.

Equities

USRM

US90350U1007

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 20:42:59 02/05/2024 BST 		5-day change 1st Jan Change
0.000001 USD -99.00% Intraday chart for U.S. Stem Cell, Inc. 0.00% 0.00%
2023 U.S. Stem Cell, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2023 U.S. Stem Cell, Inc. Auditor Raises 'Going Concern' Doubt CI

Business Summary

U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.

Number of employees: 11

Sales per Business

USD in Million2021Weight2022Weight Delta
Autologous Cell Therapies
100.0 %
0 100.0 % 0 100.0 % -59.13%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -59.13%

Managers

Managers TitleAgeSince
Miguel Tomás CEO
 Chief Executive Officer 58 31/12/02
Mark Borman CHM
 Chairman 69 30/04/09

Members of the board

Members of the board TitleAgeSince
Greg Knutson BRD
 Director/Board Member 72 04/03/17
William P. Murphy BRD
 Director/Board Member 100 31/05/03
Mark Borman CHM
 Chairman 69 30/04/09
Miguel Tomás CEO
 Chief Executive Officer 58 31/12/02
Sheldon Anderson BRD
 Director/Board Member 73 27/08/13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 641,507,317 571,247,298 ( 89.05 %) 0 89.05 %

Shareholders

NameEquities%Valuation
Northstar Biotech Group LLC
6.311 %
40,484,376 6.311 % - $
Greg Knutson
4.548 %
29,175,000 4.548 % - $
Mark Borman
0.0821 %
526,942 0.0821 % - $
William P. Murphy
0.009896 %
63,481 0.009896 % - $
Miguel Tomás
0.001291 %
8,279 0.001291 % - $
Sheldon Anderson
0.000303 %
1,941 0.000303 % - $

Company contact information

U.S. Stem Cell, Inc.

1560 Sawgrass Corporate Parkway 4th floor

33323-6217, Sunrise

+954 835 1500

http://www.us-stemcell.com
address U.S. Stem Cell, Inc.(USRM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
U.S. STEM CELL, INC. Stock U.S. Stem Cell, Inc.
0.00% 661
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.70% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+9.93% 105B
ARGENX SE Stock argenx SE
+1.57% 23.46B
BIONTECH SE Stock BioNTech SE
-12.06% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.70% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.01% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.90% 12.53B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. USRM Stock
  4. Company U.S. Stem Cell, Inc.